case_images: PMC10776590_01
case_images: Rapid resolution of edema in a HER2-positive breast cancer patient with metastatic involvement of the brain. (A) Brain lesions at baseline. The first infusion of bevacizumab was given on September 6, 2022, when the patient was in coma; (B) MRI examination was performed on day 30 after the start of this treatment. Monotherapy with bevacizumab resulted in a significant reduction of the perifocal swelling in the left hemisphere of the cerebellum (red star); there is also a resolution of the compression of the pontine cistern and the fourth ventricle (orange arrows)
case_images: etat-04-1002189-g001.jpg
case_images: PMC10776590_01_etat-04-1002189-g001.jpg
case_images: fig1
case_images: Magnetic resonance imaging (MRI) examination was carried out at the beginning of October and demonstrated the resolution of the edema (Figure 1).
case_images: PMC10776590_02
case_images: Regression of brain metastases in response to bevacizumab therapy. (A) Metastatic lesions in the brain at baseline. Bevacizumab infusions were started on September 16, 2023; (B) MRI examination was carried out on day 24 after the first dose of this drug. The reduction of the size of metastatic lumps is observed in the pons Varolii (from 19 mm x 15 mm to 13 mm x 8 mm and from 14 mm x 8 mm to 8 mm x 5 mm, blue arrow) and in the right hemisphere of the cerebellum (from 11 mm x 10 mm to 9 mm x 6 mm, green arrow). The sum of diameters of target lesions has been reduced by 32%
case_images: etat-04-1002189-g002.jpg
case_images: PMC10776590_02_etat-04-1002189-g002.jpg
case_images: fig2
case_images: MRI examination on October 10, 2022, revealed a reduction in the size of some brain metastases (Figure 2).
case_images: PMC10776590_03
case_images: The response of metastatic lesions located in the right temporal lobe to a single-agent bevacizumab therapy. (A) Metastatic lump at baseline. Bevacizumab therapy was started on December 8, 2022; (B) MRI imaging was performed on day 54 after the initiation of this treatment. The baseline size of the metastasis is 24 mm x 21 mm (green arrow, left), while a 45% reduction in the tumor size was observed in the next examination (13 mm x 12 mm; green arrow, right)
case_images: etat-04-1002189-g003.jpg
case_images: PMC10776590_03_etat-04-1002189-g003.jpg
case_images: fig3
case_images: Figure 3). Furthermore, the resolution of brain edema was observed (data not shown).
case_images: PMC10776590_04